Search

Your search keyword '"Nanni O"' showing total 466 results
Start Over Author "Nanni O"
466 results on '"Nanni O"'

1. IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab

Author

Marisi G, Scarpi E, Passardi A, Nanni O, Pagan F, Valgiusti M, Casadei Gardini A, Neri LM, Frassineti GL, Amadori D, and Ulivi P

Subjects
serum biomarkers, targeted therapy, IL-8, angiogenesis, chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Giorgia Marisi,1 Emanuela Scarpi,2 Alessandro Passardi,3 Oriana Nanni,2 Flavia Pagan,2 Martina Valgiusti,3 Andrea Casadei Gardini,3 Luca Maria Neri,4 Giovanni Luca Frassineti,3 Dino Amadori,3 Paola Ulivi1 1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; 2Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; 3Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola 47014, Italy; 4Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara 44100, Italy Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome.Patients and methods: Serum samples collected at baseline and at the first clinical evaluation were available for 58 patients enrolled in the randomized multicenter ITACa trial and who received CT+ B. Serum protein levels were determined using multiplex ELISA.Results: Patients with baseline ≥145 pg/mL IL-8 showed shorter median progression-free survival and overall survival (OS) than those with lower levels (6.5 vs 6. 12.6 months; HR 7.39, P

Published
2018

2. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET

Author

Malagutti, Bianca, Dib, Bassam, Branni, Carmen, D’Amico, Mauro, Provinciali, Nicoletta, Corradengo, Davide, Fiz, Francesco, Iacozzi, Massimiliano, Rocca, Andrea, Gennari, A., Brain, E., De Censi, A., Nanni, O., Wuerstlein, R., Frassoldati, A., Cortes, J., Rossi, V., Palleschi, M., Alberini, J.L., Matteucci, F., Piccardo, A., Sacchetti, G., Ilhan, H., D’Avanzo, F., Ruffilli, B., Nardin, S., Monti, M., Puntoni, M., Fontana, V., Boni, L., and Harbeck, N.

Published
2024
Full Text
View/download PDF

3. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial

Author

Grassi, E., Zingaretti, C., Petracci, E., Corbelli, J., Papiani, G., Banchelli, I., Valli, I., Frassineti, G.L., Passardi, A., Di Bartolomeo, M., Pietrantonio, F., Gelsomino, F., Carandina, I., Banzi, M., Martella, L., Bonetti, A.V., Boccaccino, A., Molinari, C., Marisi, G., Ugolini, G., Nanni, O., and Tamberi, S.

Published
2023
Full Text
View/download PDF

4. Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET

Author

Gennari, A., primary, Brain, E., additional, De Censi, A., additional, Nanni, O., additional, Wuerstlein, R., additional, Frassoldati, A., additional, Cortes, J., additional, Rossi, V., additional, Palleschi, M., additional, Alberini, J.L., additional, Matteucci, F., additional, Piccardo, A., additional, Sacchetti, G., additional, Ilhan, H., additional, D’Avanzo, F., additional, Ruffilli, B., additional, Nardin, S., additional, Monti, M., additional, Puntoni, M., additional, Fontana, V., additional, Boni, L., additional, Harbeck, N., additional, Malagutti, Bianca, additional, Dib, Bassam, additional, Branni, Carmen, additional, D’Amico, Mauro, additional, Provinciali, Nicoletta, additional, Corradengo, Davide, additional, Fiz, Francesco, additional, Iacozzi, Massimiliano, additional, and Rocca, Andrea, additional

Published
2024
Full Text
View/download PDF

7. Smoking and Hematolymphopoietic Malignancies

Author

Stagnaro, E., Ramazzotti, V., Crosignani, P., Fontana, A., Masala, G., Miligi, L., Nanni, O., Neri, M., Rodella, S., Costantini, A. Seniori, Tumino, R., Viganò, C., Vindigni, C., and Vineis, P.

Published
2001

8. Radiotherapy and palliative care outpatient clinic: a new healthcare integrated model in Italy

Author

Rossi R., Foca F., Tontini L., Pieri M., Micheletti S., Nanni O., Altini M., Massa I., Pallotti M. C., Ricci M., Romeo A., Muolo M. G., Galeotti G., Valenti V., Tenti M. V., Donati C. M., Pensieri M. V., Morganti A. G., Maltoni M., Rossi R., Foca F., Tontini L., Pieri M., Micheletti S., Nanni O., Altini M., Massa I., Pallotti M.C., Ricci M., Romeo A., Muolo M.G., Galeotti G., Valenti V., Tenti M.V., Donati C.M., Pensieri M.V., Morganti A.G., and Maltoni M.

Subjects
Oncology, Palliative care, Palliative radiotherapy, Symptom management, Aggressiveness of care
Abstract

Background On the basis of substantial evidence demonstrate that palliative care combined with standard care improves patient, caregiver, and society outcomes, we have developed a new healthcare model called radiotherapy and palliative care (RaP) outpatient clinic were a radiation oncologist and a palliative care physician make a joint evaluation of advanced cancer patients. Methods We performed a monocentric observational cohort study on advanced cancer patients referred for evaluation at the RaP outpatient clinic. Measures of quality of care were carried out. Results Between April 2016 and April 2018, 287 joint evaluations were performed and 260 patients were evaluated. The primary tumor was lung in 31.9% of cases. One hundred fifty (52.3%) evaluations resulted in an indication for palliative radiotherapy treatment. In 57.6% of cases was used a single dose fraction of radiotherapy (8 Gy). All the irradiated cohort completed the palliative radiotherapy treatment. An 8% of irradiated patients received the palliative radiotherapy treatment in the last 30 days of life. A total of 80% of RaP patients received palliative care assistance until the end of life. Conclusion At the first descriptive analysis, the radiotherapy and palliative care model seem to respond to the need of multidisciplinary approach in order to obtain an improvement on quality of care for advanced cancer patients.

Published
2023

10. Coffee consumption and risk of non-Hodgkin’s lymphoma: evidence from the Italian multicentre case–control study

Author

Parodi, Stefano, Merlo, Franco Domenico, Stagnaro, Emanuele, Crosignani, P., Fontana, A., Miligi, L., Masala, G., Nanni, O., Ramazzotti, V., Rodella, S., Costantini, A. Seniori, Tumino, R., Viganò, C., Vindigni, C., Vineis, P., and On behalf of the Working Group for the Epidemiology of Hematolymphopoietic Malignancies in Italy

Published
2017
Full Text
View/download PDF

11. 221P Early prediction of efficacy of endocrine therapy (ET) in metastatic breast cancer (MBC): Pilot study with [18F]fluoro-estradiol-17β (18F-FES) PET/CT

Author

Gennari, A., primary, Brain, E.G.C., additional, Nanni, O., additional, Harbeck, N., additional, Cortés, J., additional, De Censi, A., additional, Piccardo, A., additional, Alberini, J.L., additional, Matteucci, F., additional, Sacchetti, G., additional, Ilhan, H., additional, Monti, M., additional, Wuerlestein, R., additional, Saggia, C., additional, Rossi, V., additional, D'Avanzo, F., additional, Maggiora, P.M., additional, Iacozzi, M., additional, Frassoldati, A., additional, and Boni, L., additional

Published
2022
Full Text
View/download PDF

15. 1497P Cancer patients’ awareness about clinical research: The ELPIS study preliminary results

Author

Cagnazzo, C., primary, Franchina, V., additional, Toscano, G., additional, Fagioli, F., additional, Franchina, T., additional, Ricciardi, G.R.R., additional, Antonuzzo, L., additional, Di Costanzo, A., additional, Russo, A., additional, Cusenza, S., additional, Gori, S., additional, Marchetti, F., additional, Tambaro, M., additional, Piccirillo, P., additional, Nanni, O., additional, Delfanti, S., additional, Di Maio, M., additional, D'Ascanio, F., additional, and Adamo, V., additional

Published
2021
Full Text
View/download PDF

21. 41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial

Author

Conte, P.F., primary, Frassoldati, A., additional, Bisagni, G., additional, Brandes, A.A., additional, Donadio, M., additional, Garrone, O., additional, Piacentini, F., additional, Cavanna, L., additional, Giotta, F., additional, Aieta, M., additional, Gebbia, V., additional, Musolino, A., additional, Ferro, A., additional, Danese, S., additional, Zamagni, C., additional, Nanni, O., additional, Dieci, M.V., additional, Vicini, R., additional, Balduzzi, S., additional, and Guarneri, V., additional

Published
2021
Full Text
View/download PDF

22. GOSAFE - Geriatric Oncology Surgical Assessment and Functional rEcovery after Surgery: early analysis on 977 patients

Author

Montroni, I, Rostoft, S, Spinelli, A, Van Leeuwen, BL, Ercolani, G, Saur, NM, Jaklitsch, MT, Somasundar, PS, Carino, ND, Ghignone, F, Foca, F, Zingaretti, C, Audisio, RA, Ugolini, G, Garutti, A, Taffurelli, G, Zattoni, D, Tramelli, P, Sermonesi, G, Di Candido, F, Carvello, M, Sacchi, M, De Lucia, F, Foppa, C, Plas, M, Van der Wal-Huisman, H, Tauceri, F, Perenze, B, Di Pietrantonio, D, Mirarchi, M, Fejka, M, Bleier, JIS, Frain, L, Fox, SW, Cardin, K, De Leon, LE, Baltatzis, M, Chan, AKC, Siriwardena, AK, Vertogen, B, Nanni, O, Garulli, G, Alagna, V, Pirrera, B, Lucchi, A, Monari, F, Conti, L, Capelli, P, Romboli, A, Palmieri, G, Banchini, F, Marano, L, Spaziani, A, Castagnoli, G, Bartoli, A, Trompetto, M, Gallo, G, Luc, AR, Clerico, G, Sammarco, G, De Luca, R, Barile, G, Simone, M, Costanzi, A, Mari, G, Maggioni, D, Pellegrino, R, Riggio, V, Kenig, J, Szabat, K, Scabini, S, Pertile, D, Stratta, E, Massobrio, A, Soriero, D, Nesbakken, A, Lonn, M, Backe, IF, Ferrari, G, Mazzola, M, Alampi, BDA, Achilli, P, Sfondrini, S, Ioannidis, O, Loutzidou, L, Galanos-Demiris, K, Pellino, G, Balducci, G, Frezza, B, Lucarini, A, Santos, C, Cooper, L, Siam, B, Levy, Y, Brenner, B, Kashtan, H, Belgrano, V, De Cian, F, Palermo, B, Eggenhoffner, R, Albertelli, M, Sanchez-Guillen, L, Arroyo, A, Lopez-Rodriguez, F, Lario, S, Lillo, C, Wexner, SD, SIOG Surgical Task Force, and ESSO GOSAFE Study Grp

Subjects
MULTICENTER, CANCER
Abstract

Objective: Older patients with cancer value functional outcomes as much as survival, but surgical studies lack functional recovery (FR) data. The value of a standardized frailty assessment has been confirmed, yet it's infrequently utilized due to time restrictions into everyday practice. The multicenter GOSAFE study was designed to (1) evaluate the trajectory of patients' quality of life (QoL) after cancer surgery (2) assess baseline frailty indicators in unselected patients (3) clarify the most relevant tools in predicting FR and clinical outcomes. This is a report of the study design and baseline patient evaluations. Materials & Methods: GOSAFE prospectively collected a baseline multidimensional evaluation before major elective surgery in patients (70 years) from 26 international units. Short-/mid-/Iong-term surgical outcomes were recorded with QoL and FR data. Results: 1003 patients were enrolled in a 26-month span. Complete baseline data were available for 977(97.4%). Median age was 78 years (range 70-94); 52.8% males. 968(99%) lived at home, 51.6% without caregiver. 54.4% had 3 medications, 5.9% none. Patients were dependent (ADL < 5) in 7.9% of the cases. Frailty was either detected by G8 = 2(37.4%), TUG > 20 s (5.2%) or ASAIII-IV (48.8%). Major comorbidities (CACI > 6) were detected in 36%; 20.9% of patients had cognitive impairment according to Mini-Cog. Conclusion: The GOSAFE showed that frailty is frequent in older patients undergoing cancer surgery. QoL and FR, for the first time, are going to be primary outcomes of a real-life observational study. The crucial role of frailty assessment is going to be addressed in the ability to predict postoperative outcomes and to correlate with QoL and FR. (C) 2019 Elsevier Ltd. All rights reserved.

Published
2020

25. 19P PIK3CA mutations in HER2-positive early breast cancer patients enrolled in the adjuvant randomized short-HER study

Author

Guarneri, V., primary, Dieci, M.V., additional, Bisagni, G., additional, Brandes, A.A., additional, Frassoldati, A., additional, Cavanna, L., additional, Musolino, A., additional, Giotta, F., additional, Rimanti, A., additional, Garrone, O., additional, Bertone, E., additional, Cagossi, K., additional, Nanni, O., additional, Piacentini, F., additional, Orvieto, E., additional, Curtarello, M., additional, Chic, N., additional, D'Amico, R., additional, Prat, A., additional, and Conte, P.F., additional

Published
2020
Full Text
View/download PDF

29. A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study

Author

Barbera, M.A., primary, Corbelli, J., additional, Papiani, G., additional, Grassi, E., additional, Ugolini, G., additional, Montroni, I., additional, Bartolomeo, M Di, additional, Cascinu, S., additional, Marzola, M., additional, Bonetti, A., additional, Frassineti, G.L., additional, Nanni, O., additional, Zattoni, D., additional, Ghignone, F., additional, Taffurelli, G., additional, Pinto, C., additional, Moretti, C Carli, additional, Rossi, G., additional, Palazzi, S., additional, and Tamberi, S., additional

Published
2019
Full Text
View/download PDF

31. Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma

Author

Guida M, Riccobon A, BIASCO, GUIDO, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R, Italian Melanoma Intergroup, Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R, and Italian Melanoma Intergroup (IMI)

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Multivariate analysis, medicine.medical_treatment, Dermatology, Vinblastine, Basal (phylogenetics), Immune system, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Immunologic Factors, Receptor, Melanoma, Aged, Chemotherapy, Univariate analysis, Interleukin-6, business.industry, Interleukin-8, Middle Aged, medicine.disease, Interleukin-12, Receptors, Interleukin-6, Survival Analysis, Interleukin-10, Dacarbazine, Survival Rate, Cytokine, Cytokines, Interleukin-2, Female, Cisplatin, business
Abstract

Cytokines play a crucial role in the host's immune response. In melanoma patients, cytokine profiles seems to be related to the clinical course and their imbalance could be associated to tumour progression. Thus, we studied a panel of baseline cytokines and their behaviour during treatment in order to verify their correlation with clinical outcomes. Interleukin-6, interleukin-8, interleukin-10, interleukin-12 and soluble receptor of interleukin-2 were evaluated in 90 out of 176 metastatic melanoma patients enrolled in a phase III study comparing chemotherapy and biochemotherapy. We divided patients into three different groups according to their own cytokine levels (low, intermediate and high) and then we correlated these groups with some clinical features. We also monitored the cytokines during the treatment in a subgroup of 37 patients. In univariate analysis, higher values of interleukin-6 (P = 0.005), soluble receptor of interleukin-2 (P = 0.001) and interleukin-12 (P = 0.010) were correlated with a worse survival. Conversely, interleukin-8 was unable to discriminate patients with different prognoses, and interleukin-10 was undetectable in the majority of patients. In multivariate analysis, only soluble receptor of interleukin-2 maintained its independent role in survival. The impact of baseline cytokines on response was insignificant. Regarding the behaviours of cytokines during treatment, the most remarkable aspect was a progressive increase of interleukin-12 and soluble receptor of interleukin-2 in patients with a better survival. In our metastatic melanoma patients, higher basal levels of interleukin-6, interleukin-12 and soluble receptor of interleukin-2 were associated with a worse survival. In contrast, a progressive increase of interleukin-12 and soluble receptor of interleukin-2 was observed during treatment in patients with a better survival.

Published
2006

33. Abstract P1-13-02: Withdrawn

Author

Guarneri, V, primary, Dieci, MV, additional, Bisagni, G, additional, Brandes, AA, additional, Frassoldati, A, additional, Cavanna, L, additional, Musolino, A, additional, Giotta, F, additional, Cavazzini, G, additional, Garrone, O, additional, Bertone, E, additional, Cagossi, K, additional, Nanni, O, additional, Ferro, A, additional, Donadio, M, additional, Aieta, M, additional, Zamagni, C, additional, Piacentini, F, additional, Maiorana, A, additional, Ragazzi, M, additional, Cucchi, MC, additional, Querzoli, P, additional, Orsi, N, additional, Curtarello, M, additional, Urso, L, additional, Amadori, A, additional, Orvieto, E, additional, Vicini, R, additional, Balduzzi, S, additional, D'Amico, R, additional, and Conte, P, additional

Published
2018
Full Text
View/download PDF

36. Quality of end of life care in patients with pancreatic cancer receiving systematic versus on-demand early palliative care at diagnosis: a secondary outcome analysis from a randomized controlled trial

Author

Brunelli, C., primary, Pigni, A., additional, Mandelli, C., additional, Bianchi, E., additional, Ferrigato, L., additional, Broglia, M.C., additional, Nanni, O., additional, Dall'Agata, M., additional, Sansoni, E., additional, Cavanna, L., additional, Dadduzio, V., additional, Garetto, F., additional, Pino, M.S., additional, Bortolussi, R., additional, Luzzani, M., additional, Giaretto, L., additional, Perfetti, E., additional, Autelitano, C., additional, Piga, M.A., additional, and Caraceni, A., additional

Published
2017
Full Text
View/download PDF

38. Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intra-patient heterogeneity in metastatic breast cancer (MBC): A European TRANSCAN program

Author

Gennari, A., primary, Brain, E., additional, Nanni, O., additional, Muñoz Couselo, E., additional, Harbeck, N., additional, Geiss, R., additional, Rocca, A., additional, Cortés, J., additional, Degenhardt, T., additional, Piccardo, A., additional, Albérini, J-L., additional, Matteucci, F., additional, Decensi, A., additional, Corradengo, D.S., additional, Andreis, D., additional, Marra, D., additional, Gebhart, G., additional, Brambati, C., additional, Amadori, D., additional, and Bruzzi, P., additional

Published
2017
Full Text
View/download PDF

39. 663TiP - A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study

Author

Barbera, M.A., Corbelli, J., Papiani, G., Grassi, E., Ugolini, G., Montroni, I., Bartolomeo, M Di, Cascinu, S., Marzola, M., Bonetti, A., Frassineti, G.L., Nanni, O., Zattoni, D., Ghignone, F., Taffurelli, G., Pinto, C., Moretti, C Carli, Rossi, G., Palazzi, S., and Tamberi, S.

Published
2019
Full Text
View/download PDF

40. Phase II randomised clinical study of metformin plus chemotherapy vs chemotherapy alone in HER2 negative metastatic breast cancer: final results of the MYME trial

Author

Gennari, A., primary, Nanni, O., additional, Rocca, A., additional, De Censi, A., additional, Fieschi, A., additional, Bologna, A., additional, Gianni, L., additional, Rosetti, F., additional, Amaducci, L., additional, Cavanna, L., additional, Foca, F., additional, Sarti, S., additional, Serra, P., additional, Valmorri, L., additional, Corradengo, D., additional, Antonucci, G., additional, Bruzzi, P., additional, and Amadori, D., additional

Published
2016
Full Text
View/download PDF

43. ERA-Net TRANSCAN JTC 2011: Critical aspects of the startup procedures of an International Academic Clinical trial (ET-FES), funded by the European Community (EC) and coordinated by an Italian Institution.

Author

Monti, M., primary, Corradengo, D., additional, Nanni, O., additional, Piccardo, A., additional, Matteucci, F., additional, Brain, E., additional, Cortes, J., additional, Harbeck, N., additional, Wuerstlein, R., additional, Piris, A., additional, Merlo, D.F., additional, Degenhardt, T., additional, Cesario, A., additional, Rivitti, E., additional, Rollandi, G.A., additional, Iacozzi, M., additional, Campazzi, E., additional, Campora, S., additional, Camporese, D., additional, and Gennari, A., additional

Published
2016
Full Text
View/download PDF

44. The patients' understanding of clinical research

Author

Rudnas, B., primary, Montanari, E., additional, Dall'Agata, M., additional, Petracci, E., additional, Serra, P., additional, Piancastelli, A., additional, Vertogen, B., additional, Zumaglini, F., additional, Venturini, B., additional, Testoni, S., additional, Gallà, V., additional, Monti, M., additional, Andreis, D., additional, Pagan, F., additional, Ragazzini, A., additional, Fabbri, F., additional, Gentili, G., additional, Affatato, A., additional, and Nanni, O., additional

Published
2016
Full Text
View/download PDF

45. ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS Study

Author

Casadei Gardini, A., primary, Marisi, G., additional, Faloppi, L., additional, Scarpi, E., additional, Foschi, F.G., additional, Iavarone, M., additional, Lauletta, G., additional, Corbelli, J., additional, Tenti, E., additional, Facchetti, F., additional, della Corte, C., additional, Tamberi, S., additional, Cascinu, S., additional, Scartozzi, M., additional, Amadori, D., additional, Nanni, O., additional, Ulivi, P., additional, and Frassineti, G.L., additional

Published
2016
Full Text
View/download PDF

47. Nurses and Clinical Research Coordinators (CRCs) collaboration to improve quality in clinical trials

Author

Zeneli, A., primary, Serra, P., additional, Rosanna, T., additional, Marina, B., additional, Andreis, D., additional, Arjocan, O.R., additional, Gallà, V., additional, Golinucci, M., additional, Fabbri, F., additional, Braghesiu, P., additional, Gentili, G., additional, Zavoiu, V., additional, Nanni, C., additional, Monti, M., additional, Filograna, A., additional, Fiumicelli, T., additional, Ragazzini, A., additional, Beniamino, F., additional, Testoni, S., additional, Barlati, I., additional, and Nanni, O., additional

Published
2015
Full Text
View/download PDF

48. IRST WL: a tool to measure the workload of clinical research coordinators in oncology

Author

Fabbri, F., primary, Vertogen, B., additional, Serra, P., additional, Andreis, D., additional, Dall'Agata, M., additional, Gallà, V., additional, Gentili, G., additional, Massa, I., additional, Montanari, E., additional, Monti, M., additional, Pagan, F., additional, Piancastelli, A., additional, Polli, V., additional, Ragazzini, A., additional, Rudnas, B., additional, Testoni, S., additional, Venturini, B., additional, Zumaglini, F., additional, and Nanni, O., additional

Published
2015
Full Text
View/download PDF

50. eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Final results of ePHAS study

Author

Casadei Gardini, A., primary, Marisi, G., additional, Scartozzi, M., additional, Faloppi, L., additional, Foschi, F., additional, Corbelli, J., additional, Scarpi, E., additional, Iavarone, M., additional, Lauletta, G., additional, Ulivi, P., additional, Tamberi, S., additional, Nanni, O., additional, Cascinu, S., additional, Tenti, E., additional, and Frassineti, G.L., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results